ePAG EXCHANGE OF GOOD PRACTICES

18 March 2021





PHONE

+44 7766 745 904


EMAIL

dan@cats-foundation.org

ABOUT ME

Head of Business Development at a med-tech company and the Co-Founder of the rare disease charity The Cure & Action for Tay-Sachs (CATS) Foundation.

I know the challenges we all face in the rare disease world to get research started but utilizing real-world evidence it's possible to kick start engagement and excitement about your disease community with pharma.



THE CATS FOUNDATION WAS BORN



LOOKED INTO RESEARCH

Investigated what research was being undertaken into Tay-Sachs and Sandhoff disease

RAISED OUR PROFILE WITHIN THE COMMUNITY

We reached out to families across Europe to create a strong community to support each other

RAISED OUR PROFILE WITH RESEARCH

We reached out to all the research teams we found to let them know that we charity existed













OUR EUROPEAN CONSORTIUM

Member charities of the European Tay-Sachs and Sandhoff Charity Consortium (ETSCC). Since it was established in 2012 the ETSCC has 5 different member organisations.

TEAMWORK MAKES

DREAM WORK

== the=

COLLABORATION IS KEY

TOGETHER WE CAN
DEVELOP A TREATMENT

Working as a team, patient group, pharma, researchers and patients, can make a difference and really drive forward projects.

RESEARCH & TRIALS – 2011

In 2011 there was only one research project

1

UK

Gene therapy programme for GM2 Gangliosidosis - The University of Cambridge



RESEARCH & TRIALS – 2021

Huge progress in 10 years

7 Europe

Gene therapy programme for GM2 Gangliosidosis — The University of Cambridge IB1001-202 clinical trial — Intrabio AMETHIST (substrate reduction therapy) — Sanofi

A new inflammasome complex treatment for GM2 Gangliosidosis - Seville University

Gene transfer in a murine model of Sandhoff using AAV9 — Institut Necker Enfants Malades

Deployment of chaperone treatment for Tay-Sachs — Laboratory PR Yves Bleriot-Poitier

Investigation into gene & cellular therapy treatment for GM2 — San Raffaele Institute

2 Outside Europe Gene therapy programme — Taysha

Gene therapy programme — Sio Gene Therapies

3 Upcoming

Drug repurposing — Confidential

New drug - Pharma company — Confidential


New drug - Pharma company — Confidential



HOW TO DEVELOP GOOD PROMS FOR YOUR OWN DISEASE?

How to start the process? How to collect and bring patient views?

FIRST STEPS



TERMINOLOGY

Understand the different types of data that can be collected

DISEASE

Understand the disease from all stakeholder view points


ENGAGEMENT

Understand how best to engage with all stakeholders

COLLABORATION

Understand how collaborating can make a big difference

WHAT IS WHAT?




GOAL SETTING

WHO'S INVOLVED IN THE GOAL?

Defining who is involved in achieving the goal is vital

HOW DO WE WORK TO THE GOAL?

How do we work towards achieving the goal




WHAT IS THE GOAL?

We need to set a goal which is achievable


HOW DO WE SET THE GOAL?

What is the process at setting the goal

WHO ARE THE STAKEHOLDERS?



SETTING THE GOAL



LISTEN

It's important to listen to all stakeholders and hear their views

BE BRAVE

We want to make the biggest impact – so be bold and brave

LEARN


Learn what is important to each group and how it can impact the goal

PATIENT FIRST

The patient SHOULD and MUST be at the forefront of the discussion

HOW DO WE WORK TOGETHER?





COLLABORATION

Relevance is all a matter of perspective.

What is important to you may not be to me and vice versa.



NURTURING THE IDEA AND MAKING IT GROW



PLANT

Your collaborative idea is "planted" together as a group



NURTURE

You can all nurture the idea to make it grow in to reality




REALISE

If you all work together you can realise that goal

THE DIGITAL REVOLUTION

Every patient, like every rare disease is different and the way they manage their condition can vary



TECHNOLOGY AND THE PATIENT

The patient voice is becoming more and more important, and it can shape the way that clinical studies can be developed




Technology can support patient engagement and compliance through ease of use and with a patient focus design

Studies can potentially be completed much more rapidly due to the amount of data and frequency of assessments, reduced site and patient burden

Objective, high-frequency data, all captured in real time, to support endpoint validation whilst generating longitudinal data for real world evidence

WHY IS THIS IMPORTANT?



TIMED UP AND GO (TUG)

The originally developed TUG assesses mobility, balance, walking ability, and fall risk in older adults

- · Patients wear their regular footwear and can use a walking aid, if needed
- They begin by having the patient sit back in a standard arm chair and identify a line 3 meters, or 10 feet away, on the floor:
 - From word "Go" the patient is to:
 - Stand up from the chair
 - Walk to the line on the floor at your normal pace.
 - Turn 180 degrees
 - Walk back to the chair at your normal pace
 - Turn to Sit down again
- In the original method, the patient will be timed from the word 'Go" until they sit down again

MODIFIED TUG WITH COMPUTER VISION (VTUG)

The vTUG enables high frequency, objective assessment from the comfort of the patient's home

The Future of Assessing Disease Progression

By identifying key-points on the physical feature being measured in each frame, pattern recognition analysis can be performed via video analytics

The software locates specific points on what is being measured and provides a confidence value associated with each point. The analysis can compute the speed and trajectory of each movement, which can be used to explore smoothness of motion and erratic patterns.





MODIFIED TUG WITH COMPUTER VISION (VTUG)


Conducting a video recorded TUG (vTUG) as home and utilizing computer vision capabilities is expected to be a more sensitive way to measure disease presentation

Computer vision
techniques can be
applied to extract
parameters of interest
such as postural angles,
movement within a
plane, gait
measurements etc.

Automatic
identification of the
TUG components or
gait phases are then
feasible through
machine learning
classification
algorithms

HEEL-TOE ALIGNMENT







The vertical location of the heel and toe during the walking section of the video is then reflected by patterns of movement - heel above toe, followed by toe above heel etc. and one can see the results to be evaluated in the graph


ARM MOVEMENT









ALIGNMENT







MODIFIED TUG WITH COMPUTER VISION (VTUG)

Measuring disease progression in a way that is clinically meaningful is of utmost of importance and this technology potentially provides a novel mechanism to support this

Technology can be used to digitally collected data and computer vision software to update/modify the way assessments are used to calculate progression with the aim to provide more subjective, highly sensitive, frequent results

QUESTIONS

WHAT CAN ERNS DO IN THE AREA OF QOL MEASUREMENT?

How to bring them in the context of the ERNs?

WHAT IS QUALITY OF LIFE

- Quality of life is determined by:
 - The extent to which hopes, and ambitions are matched by experience
 - Individuals' perceptions of their position in life taken in the context of the culture and value systems where they live and in relation to their goals, expectations, standards, and concerns
 - Appraisal of one's current state against some ideal
 - The things people regard as important in their lives

Carr AJ, Higginson IJ. Are quality of life measures patient centred?. *BMJ*. 2001;322(7298):1357-1360. doi:10.1136/bmj.322.7298.1357

WHAT DOES IT SHOW?




society believe constitutes quality of life for people who

are ill?



Do they capture patients' perspectives of their disease and treatment, their perceived need for health care, and their preferences for treatment and outcomes?

WHAT ARE YOU ASKING?



BUILDING A PICTURE OF THE DISEASE IMPACT



ASKING THE PATIENT

Asking the patient means that you can build an accurate picture of the disease

CREATING A MESSAGE

A QoL can build a message about the disease that can help improve an understanding of the it


FINDING A SOLUTION

We are all trying to find a treatment / cure for our disease and an effective QoL can help

EQ-5D-5L - PAPER VERSION



Under each heading, please tick the ONE box that best describes your health TODAY. I have no problems in walking about I have slight problems in walking about I have moderate problems in walking about I have severe problems in walking about I am unable to walk about SELF-CARE I have no problems washing or dressing myself I have slight problems washing or dressing myself I have moderate problems washing or dressing myself I have severe problems washing or dressing myself I am unable to wash or dress myself USUAL ACTIVITIES (e.g. work, study, housework, family or leisure activities) I have no problems doing my usual activities I have slight problems doing my usual activities I have moderate problems doing my usual activities I have severe problems doing my usual activities I am unable to do my usual activities PAIN / DISCOMFORT I have no pain or discomfort I have slight pain or discomfort I have moderate pain or discomfort I have severe pain or discomfort I have extreme pain or discomfort ANXIETY / DEPRESSION I am not anxious or depressed I am slightly anxious or depressed I am moderately anxious or depressed I am severely anxious or depressed I am extremely anxious or depressed © 2009 EuroQol Research Foundation. EQ-5D™ is a trade mark of the EuroQol Research Foundation. UK (English) v1.2



THINGS HAVE CHANGED A LOT

The landscape for a patient and parent / carer has changed dramatically in the last 10 years

Technology



Social media



Expectations




We have access to so much technology that can do so much more than 10 years ago

Social media has become a big part of our life as we support each other and share information Everyone has much high expectations now that they are better supported

PAPER IS NOW DIGITAL





DIGITAL IS MORE INCLUSIVE













EQ-5D-5L - DIGITAL VERSION





SUMMARY

Be prepared for a lot of work to develop something that on paper shouldn't be too tough



IT'S NOT SIMPLE

You have to be open minded in your approach

Teamwork makes the dreamwork – keep repeating this phrase (it will get tough)!



TEAMWORK IS VITAL

You're working with multiple stakeholders who all want input

You can really enforce change in developing something for your community



YOU CAN MAKE A DIFFERENCE

You CAN make change if you are PATIENT!

QUESTIONS

Contact dan@cats-foundation.org